Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry

Res Pract Thromb Haemost. 2023 Aug 26;7(6):102185. doi: 10.1016/j.rpth.2023.102185. eCollection 2023 Aug.

Abstract

•Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an acute immune TTP episode.•Caplacizumab was effective in treating acute TTP in the Italian real-world clinical setting.•Two major bleeds leading to drug discontinuation were observed.

Keywords: ADAMTS-13 protein; caplacizumab; thrombocytopenia; thrombosis; thrombotic thrombocytopenic purpura.